Vera Therapeutics, Inc. Class A VERA 深 沪
等待开盘 03-27 09:30:00 美东时间
40.24
+0.080
+0.20%
华盛通- 最 高45.375
- 今 开39.46
- 成交量 50.97万股
- 最 低 37.51
- 昨 收 40.16
- 总市值 108.96万
- 52周最高 56.05
- 市盈率 静 --
- 换手率 1882.28%
- 52周最低 18.53
- 委 比 -37.67%
- 总股本 2.71万
- 历史最高 56.05
- 量 比 0.41
- 振 幅 19.58%
- 历史最低 1.10
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FDA Fast-Tracks Vera's At-Home Kidney Drug
Vera Therapeutics stock rose on FDA acceptance of atacicept BLA for priority review in IgAN, a potential multi-billion dollar market.
01-08 01:29
一代鞋王，彪马要卖了
原标题：一代鞋王，彪马要卖了 这一幕仍在继续。 据彭博社报道，知名运动品牌彪马（Puma）市值过去一年大幅缩水，身后皮诺家族开始接触潜在买家。换言之，彪马要被...
2025-08-31 15:16
日本平面设计大展“一天世界”亮相上海，超300件原作展出
（来源：上观新闻） 7月26日，“一天世界：Graphic Design in Japan”中国巡展上海站在复星艺术中心开幕。展览由日本平面...
2025-07-26 18:52
中国创新药下一个BD大机会，藏不住了
TACI赛道的热度已经藏不住了。从前几年在该赛道偶发零星BD交易，到今年短短半年内已经达成4笔交易，尤其是荣昌生物的泰它西普在近期以超40亿美元的总额实现出海...
2025-07-07 08:22
Vera Bradley Announces Management and Board Leadership Changes
Vera Bradley announced that CEO Jacqueline Ardrey will be departing, with Ian Bickley assuming the role of Executive Chairman and Martin Layding joining as CFO. The Board has also established a new Strategy and Transformation Committee to guide the Company's future growth.
2025-06-11 12:00
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera TherapeuticsGranted Stock Options and RSUs to 17 New Employees in Compliance with Nasdaq Rule, with Options and RSUs Vesting Over Four Years.
2025-06-09 20:05
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Vera Therapeutics Inc. announced that its management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025, at 3:15pm EDT, with a webcast available and replay for 90 days.
2025-06-04 20:05
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy
Vera Therapeutics announced that its ORIGIN Phase 3 trial for atacicept met the primary endpoint of reducing proteinuria (UPCR) by 46% from baseline and 42% compared to placebo at week 36 (p<0.0001). Atacicept also demonstrated favorable safety and improved or consistent results on other endpoints compared to Phase 2b. Vera plans to submit a BLA for accelerated approval in Q4 2025, targeting a potential US launch in 2026, with final two-year trial results expected in 2027.
2025-06-02 10:30
Cantor Fitzgerald Reiterates Overweight on Vera Therapeutics, Maintains $107 Price Target
Cantor Fitzgerald analyst Pete Stavropoulos reiterates Vera Therapeutics (NASDAQ:VERA) with a Overweight and maintains $107 price target.
2024-09-06 21:52
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Nasdaq Composite falling around 2% on Tuesday. Shares of Vaxcyte, Inc. (NASDAQ:PCVX) rose sharply during Tuesday's session after the company released topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the compan...
2024-09-03 22:47
